Di Nola F, Arione R, Bramato C
Ospedale Amedeo di Savoia, Torino.
Minerva Med. 1991 Oct;82(10):633-56.
The microbiological, kinetic and clinical profile of cefixime, a IIIrd generation cephalosporin, administered orally, is presented. Cefixime is highly active versus Gram-negative aerobic bacteria while, with respect to Gram-positive bacteria, it is only active against Str. pneumoniae, Str. pyogenes, Str. agalactiae, and Str. bovis. It has no action against anaerobics. Endowed with good kinetics, cefixime possesses a favourable tissue distribution. Cefixime is highly indicated in infections of the upper and lower airways where the aethiology is prevalently due to Str. pneumoniae, H. influenzae and B. catarrhalis, that are extremely sensitive to the antibiotic. It is concluded that the therapeutic armamentarium has been enriched by a new, highly active antibiotic that, administered in a monodese/die, ca satisfy patient compliance.
本文介绍了口服第三代头孢菌素头孢克肟的微生物学、动力学和临床概况。头孢克肟对革兰氏阴性需氧菌具有高度活性,而对于革兰氏阳性菌,它仅对肺炎链球菌、化脓性链球菌、无乳链球菌和牛链球菌有活性。它对厌氧菌无作用。头孢克肟具有良好的动力学特性,组织分布良好。在上、下呼吸道感染中,当病因主要是对该抗生素极为敏感的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌时,头孢克肟具有高度适用性。结论是,一种新型、高活性的抗生素丰富了治疗药物库,该抗生素每日单次给药即可满足患者的依从性。